645-05-6

• 常用中文名：2,4,6-三(二甲氨基)均三嗪
• 常用英文名：Altretamine
• CAS号：645-05-6
• 分子式：C₉H₁₈N₆
• 分子量：210.279
• 相关类别： 原料药 抗肿瘤药 烷化剂类抗肿瘤药
• 发布时间：2018-09-06 15:11:24
• 更新时间：2026-07-02 19:45:54
• Altretamine 是一种烷化剂 (alkylator),具有抗肿瘤活性。

名称

• 中文名: 六甲蜜胺
• 英文名: hexamethylmelamine
• 中文别名: 六甲聚腈胺; 六甲三聚氰胺; N2,N2,N4,N4,N6,N6-六甲基-1,3,5-三嗪-2,4,6-三胺; 2,4,6-三(二甲氨基)均三嗪(六甲蜜胺); HEXAMETHYLMELAMINE|||NSC13875|||六甲蜜胺|||RB-1515|||ENT-50852|||WR-95704; 2，4，6-三(二甲氨基)均三嗪; 六甲密胺 标准品; 六甲蜜胺,10 MM DMSO 溶液; 六甲密胺; 六甲嘧胺
• 英文别名: 1,3,5-tris(dimethylamino)-s-triazine; N,N,N',N',N'',N''-HEXAMETHYL-1,3,5-TRIAZINE-2,4,6-TRIAMINE; Altretamine, 10 mM in DMSO; N2,N2,N4,N4,N6,N6-hexamethyl-1,3,5-triazine-2,4,6-triamine; Altretamine (RB-1515,WR-95704); Altretamine //BP; melamine,hexamethyl; Aitretamine; Hexylen; MFCD00549245; 2,4,6-TRIS(DIMETHYLAMINO)-1,3,5-TRIAZINE; Hexamethylmelamine|||NSC13875|||RB-1515|||ENT-50852|||WR-95704; AltretaMine [2; 5-triazine-2,4,6-triamine,n,n,n’,n’,n’’,n’’-hexamethyl-3; WR-95704; ALTRETAMINE, Hexamethylmelamine; ALTRETAMINE; AltretaMine(Hexalen); Hemel; N,N,N',N',N'',N''-Hexamethyl-1,3,5-triazine-2,4,6-triamine; s-Triazine, 2,4,6-tris(dimethylamino); RB-1515; ENT050852; Altretamine, >=; [4,6-bis(dimethylamino)-s-triazin-2-yl]-dimethyl-amine; ALTRETAMIN; HTM; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4,6-tris<dimethylamino>-1,3,5-triazine; 2,4,6-tris(dimethylamino)-s-triazin; EINECS 211-428-4; N,N,N’,N’,N″,N″-hexamethyl-1,3,5-triazine-2,4,6-triamine; Melamine, hexamethyl; 1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N'',N''-hexamethyl; Altretamine (ENT-50852); nsc13875; hemel; hexamethyl-melamin; 2,4,6-Tris(Dimethylamino)-s-triazine; Hexastat; HMM; Hexalen; 6-Tris(diMethylaMino)-1; HEXAMETHYLMELAMINE; ALTRETAMINE [2,4,6-TRIS(DIMETHYLAMINO)-1,3,5-TRIAZINE]; NSC-13875; ent50852; 1,3,5-Triazine-2,4,6-triamine, N2,N2,N4,N4,N6,N6-hexamethyl; N,N,N,N,N,N-Hexamethyl-1,3,5-triazine-2,4,6-triamine; NC 195; NCI-C50259

物化性质

• 密度: 1.1±0.1 g/cm3
• 沸点: 339.4±25.0 °C at 760 mmHg
• 熔点: 171-175 °C(lit.)
• 分子式: C₉H₁₈N₆
• 分子量: 210.279
• 闪点: 159.1±23.2 °C
• 精确质量: 210.159302
• PSA: 48.39000
• LogP: 2.42
• 外观性状: 无色结晶固体
• 蒸汽压: 0.0±0.7 mmHg at 25°C
• 折射率: 1.610
• 储存条件:

  常温，2-8℃，避光，通风干燥处

• 稳定性:

  白色针状结晶。熔点170-173℃，易溶于

  氯仿，微溶于甲醇、乙醇，极微溶于水，对酸碱稳定。具升华性

• 水溶解性: Insoluble
• 计算化学:

  1.疏水参数计算参考值（XlogP）:无

  2.氢键供体数量:0

  3.氢键受体数量:6

  4.可旋转化学键数量:3

  5.互变异构体数量:无

  6.拓扑分子极性表面积48.4

  7.重原子数量:15

  8.表面电荷:0

  9.复杂度:148

  10.同位素原子数量:0

  11.确定原子立构中心数量:0

  12.不确定原子立构中心数量:0

  13.确定化学键立构中心数量:0

  14.不确定化学键立构中心数量:0

  15.共价键单元数量:1

• 更多:

  1. 性状：白色针状结晶

  2. 密度（g/mL,25/4℃）：

  3. 相对蒸汽密度（g/mL,空气=1）：

  4. 熔点（ºC）：171-175

  5. 沸点（ºC,常压）：301

  6. 沸点（ºC,5.2kPa）：未确定

  7. 折射率：

  8. 闪点（ºC）：

  9. 比旋光度（º）：

  10. 自燃点或引燃温度（ºC）：

  11. 蒸气压（kPa,25ºC）：

  12. 饱和蒸气压（kPa,60ºC）：

  13. 燃烧热（KJ/mol）：

  14. 临界温度（ºC）：

  15. 临界压力（KPa）：

  16. 油水（辛醇/水）分配系数的对数值：

  17. 爆炸上限（%,V/V）：

  18. 爆炸下限（%,V/V）：

  19. 溶解性：不溶于水

生物活性

• 描述: Altretamine 是一种烷化剂 (alkylator),具有抗肿瘤活性。
• 相关类别:
  信号通路 >> 细胞周期/DNA损伤 >> DNA烷基化剂/交联剂
  研究领域 >> 癌症
• 体外研究: Altretamine是一种抗肿瘤药物[1]。
• 体内研究: Altretamine(100,133 mg/kg,ip。)与Irofulven联合使用可增加携带MV522细胞的小鼠的抗肿瘤作用[1]。
• 动物实验: 小鼠[1] Balb / c nu / nu 4周龄雌性小鼠体重18-22g，接受sc注射8-10百万MV522细胞。在肿瘤植入后第10天开始，每周三次腹膜内施用阿尔特雷明，持续3周。以两个垂直直径测量肿瘤大小，并根据下式估计肿瘤重量（TW）：w = [（宽度）2×长度/ 2]。将阿尔特赖胺制备成在40％DMSO /生理盐水中的1-10mg / mL的储备溶液，并根据需要用10％DMSO /生理盐水稀释[1]。
• 参考文献:

  [1]. Kelner MJ, et al. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model. Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26.

毒性和生态

生态学数据: 通常对水是不危害的，若无政府许可，勿将材料排入周围环境 CHEMICAL IDENTIFICATION RTECS NUMBER : OS1050000 CHEMICAL NAME : Melamine, hexamethyl- CAS REGISTRY NUMBER : 645-05-6 BEILSTEIN REFERENCE NO. : 0195058 LAST UPDATED : 199612 DATA ITEMS CITED : 26 MOLECULAR FORMULA : C9-H18-N6 MOLECULAR WEIGHT : 210.33 WISWESSER LINE NOTATION : T6N CN ENJ BN1&1 DN1&1 FN1&1 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human DOSE/DURATION : 8 mg/kg TOXIC EFFECTS : Gastrointestinal - nausea or vomiting Blood - leukopenia TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 350 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 265 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 437 mg/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - chromodacryorrhea Blood - hemorrhage TYPE OF TEST : LD10 - Lethal Dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 200 mg/kg TOXIC EFFECTS : Blood - granulocytopenia Blood - changes in bone marrow (not otherwise specified) TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 171 mg/kg TOXIC EFFECTS : Cardiac - cardiomyopathy including infarction Liver - hepatitis (hepatocellular necrosis), zonal TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 100 mg/kg TOXIC EFFECTS : Blood - pigmented or nucleated red blood cells Blood - changes in leukocyte (WBC) count Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - guinea pig DOSE/DURATION : 255 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Bird - chicken DOSE/DURATION : 341 mg/kg TOXIC EFFECTS : Peripheral Nerve and Sensation - flaccid paralysis without anesthesia (usually neuromuscular blockage) Behavioral - ataxia TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 3080 mg/kg/77D-I TOXIC EFFECTS : Gastrointestinal - changes in structure or function of endocrine pancreas Endocrine - hyperglycemia Related to Chronic Data - death TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 625 mg/kg/5D-I TOXIC EFFECTS : Related to Chronic Data - death TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 625 mg/kg/5D-I TOXIC EFFECTS : Related to Chronic Data - death TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 250 mg/kg/5D-I TOXIC EFFECTS : Blood - changes in bone marrow (not otherwise specified) Blood - other changes Related to Chronic Data - death TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 3108 mg/kg/3Y-I TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Blood - leukemia TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 7 gm/kg/46W-C TOXIC EFFECTS : Tumorigenic - neoplastic by RTECS criteria Kidney, Ureter, Bladder - Kidney tumors Skin and Appendages - tumors TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 1240 mg/kg SEX/DURATION : male 62 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females) Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 320 mg/kg SEX/DURATION : female 6-9 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 320 mg/kg SEX/DURATION : female 9-12 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 1160 mg/kg SEX/DURATION : female 15-22 day(s) after conception lactating female 21 day(s) post-birth TOXIC EFFECTS : Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 80 mg/kg SEX/DURATION : female 15-22 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 780 mg/kg SEX/DURATION : female 6-18 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) TYPE OF TEST : Sex chromosome loss and nondisjunction TYPE OF TEST : Cytogenetic analysis MUTATION DATA TYPE OF TEST : DNA damage TEST SYSTEM : Mammal - species unspecified Lymphocyte DOSE/DURATION : 250 umol/L REFERENCE : CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year: 43,500,1983

安全

• 符号: GHS07
• 信号词: Warning
• 危害声明: H302-H315-H319-H335
• 警示性声明: P261-P305 + P351 + P338
• 个人防护装备: dust mask type N95 (US);Eyeshields;Faceshields;Gloves
• 危害码 (欧洲): Xn: Harmful;
• 风险声明 (欧洲): R22;R36/37/38
• 安全声明 (欧洲): S26-S36
• 危险品运输编码: NONH for all modes of transport
• WGK德国: 3
• RTECS号: OS1050000
• 海关编码: 2933699090

上下游产品

上游产品  7
1467-79-4 108-77-0 124-40-3 123-39-7
103-83-3 51-80-9 506-59-2
下游产品  2
124-40-3 108-80-5

制备

由三氯三聚氰与二甲胺缩合而得

海关

海关编码	2933699090
中文概述	2933699090 其他结构上含非稠合三嗪环化合物. 增值税率:17.0% 退税率:9.0% 监管条件:无 最惠国关税:6.5% 普通关税:20.0%
申报要素	品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期
Summary	2933699090 other compounds containing an unfused triazine ring (whether or not hydrogenated) in the structure。Supervision conditions:None。VAT:17.0%。Tax rebate rate:9.0%。MFN tariff:6.5%。General tariff:20.0%